Ferrous Fumarate

Ferrous fumarate is elemental iron bound to fumaric acid, supplying iron in the reduced ferrous (Fe²⁺) state that the gut absorbs most readily. At roughly 33% elemental iron by weight it is the most iron-dense of the three common ferrous salts — nearly double ferrous sulfate (~20% as the heptahydrate) and about 2.5× ferrous gluconate (~12%). In practice a standard 200 mg fumarate tablet delivers about 66 mg of elemental iron, so fewer or smaller tablets are needed to hit a target dose. It is a common, inexpensive, and effective repletion salt; its gut tolerance generally sits between ferrous sulfate (least gentle) and the amino-acid chelates such as ferrous bisglycinate (gentlest). For iron’s full, form-agnostic evidence base — who benefits, effect sizes, cognition, pregnancy, restless legs — see the Iron hub; this page covers only what is specific to the fumarate form.

Absorption & Tolerability

The elemental-density advantage is real; the “better absorbed” claim is not. Fumarate’s headline benefit is density, not fractional absorption. Once dissolved, iron from fumarate is absorbed about as well as from ferrous sulfate in adults. A stable-isotope study in non-anemic Mexican women, infants and young children found no significant difference in absorption between the two salts, with relative bioavailability (RBV) of 86 in women, 97 in infants and 106 in young children ^{1Reference 1Zimmermann et al. · 2011RCTA comparison of the bioavailability of ferrous fumarate and ferrous sulfate in non-anemic Mexican women and children consuming a sweetened maize and milk drink — [randomized isotope study]View study →}. This is consistent with the historical basis for fumarate’s use in fortification: earlier adult isotope studies reported an RBV of fumarate near 100 relative to sulfate ^{3Reference 3Harrington et al. · 2010ReviewUse of ferrous fumarate to fortify foods for infants and young children — [review]View study →}. Twin-isotope work also found iron from ferrous fumarate to be as available for hemoglobin synthesis as from an iron polymaltose complex at a matched 100 mg dose, the two being usable interchangeably ^{2Reference 2Kaltwasser et al. · 1984Clinical trialOral iron therapy in human subjects: comparative absorption between ferrous salts and iron polymaltose — [comparative isotope study]View study →}.

The pediatric caveat. In young children specifically, some isotope studies found iron from ferrous fumarate was only about 30% as well absorbed as from ferrous sulfate (RBV ~30) — attributed to lower gastric acid output slowing dissolution of the poorly water-soluble fumarate salt ^{3Reference 3Harrington et al. · 2010ReviewUse of ferrous fumarate to fortify foods for infants and young children — [review]View study →}. Later data were more reassuring: fumarate-fortified complementary foods prevented iron deficiency about as well as sulfate in iron-replete infants, but reviewers still caution that fumarate may be a less reliable choice than sulfate when the goal is to treat established deficiency in the very young ^{3Reference 3Harrington et al. · 2010ReviewUse of ferrous fumarate to fortify foods for infants and young children — [review]View study →}. Co-ingesting ascorbic acid helps: in 4–8-year-olds, taking a fumarate-fortified muffin with orange juice (25 mg ascorbic acid) raised absorption from 5.5% to 8.2% versus apple juice ^{4Reference 4Mitchikpe et al. · 2010RCTOrange but not apple juice enhances ferrous fumarate absorption in small children — [randomized crossover]View study →}.

Tolerability is intermediate — with one caveat. The common framing that fumarate is “gentler than sulfate” is not strongly supported. A large systematic review of 111 studies (10,695 patients) actually recorded the highest overall adverse-event rate for ferrous fumarate among the salts tabulated (≈47% overall AEs) — though such cross-study comparisons are confounded by dose, since fumarate’s high elemental content often means more iron delivered per unit ^{5Reference 5Cancelo-Hidalgo et al. · 2013Systematic reviewTolerability of different oral iron supplements: a systematic review — [systematic review, 111 studies]View study →}. Amino-acid chelates such as bisglycinate are often marketed as gentler than conventional salts including fumarate, but the head-to-head evidence is limited and confounded by the elemental dose delivered in each arm. At low, equipotent prophylactic doses, formulation matters little: a pooled analysis of two randomized double-blind pregnancy studies found low-dose ferrous fumarate, bisglycinate and sulfate all produced only minor, clinically insignificant GI complaints ^{6Reference 6Milman et al. · 2024RCTLow-dose prophylactic oral iron supplementation (ferrous fumarate, ferrous bisglycinate, and ferrous sulphate) in pregnancy is not associated with clinically significant gastrointestinal complaints: results from two randomized studies — [pooled RCT analysis]View study →}. The practical read: tolerability is driven mostly by the elemental-iron dose, not the fumarate salt per se — lower the elemental dose or dose on alternate days before switching salts.

Gap: Direct, adequately powered head-to-head RCTs of fumarate versus sulfate using matched elemental-iron doses and tolerability as the primary endpoint are scarce; most “fumarate is gentler/harsher” claims rest on cross-study comparisons confounded by dose.

What the Evidence Says

Most large iron-efficacy trials used ferrous sulfate, so fumarate-specific outcome data are thinner — but where fumarate has been tested directly it performs as a standard, effective repletion salt. In iron-deficiency anemia it raises hemoglobin and ferritin comparably to other oral salts: a comparative study of ferrous fumarate, ferrous ascorbate, bisglycinate and Sucrosomial iron found all significantly improved hemoglobin over three months, with fumarate solidly effective though not the top performer ^{7Reference 7Comparative evaluation of different oral · 2024ObservationalComparative evaluation of different oral iron salts in the management of iron deficiency anemia (2024) — [comparative observational study]. DARU Journal of Pharmaceutical Sciences. https://pubmed.ncbi.nlm.nih.gov/38740692/View study →}. In low-anemic/non-anemic iron-deficient adults, fumarate-based standard-of-care products raised hemoglobin and ferritin and reduced fatigue ^{8Reference 8A clinical study evaluating low dose fer · 2024Clinical trialA clinical study evaluating low dose ferrous fumarate vs. standard iron supplements in iron-deficient non-anemic to mild anemic adults (2024) — [clinical study]. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/38977742/View study →}. In pregnancy, oral fumarate corrects anemia but works more slowly and less completely than intravenous iron when deficiency is significant — IV iron sucrose produced a larger hemoglobin rise (22 vs 12 g/L at 4 weeks) than oral fumarate in one RCT ^{9Reference 9Kriplani et al. · 2017RCTIntravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy: a randomized controlled trial — [RCT]View study →} — which is a property of oral iron generally, not of the fumarate salt. Fumarate is also the reference iron compound recommended for fortifying complementary foods for infants and young children, on the strength of good sensory properties and adult absorption data ^{3Reference 3Harrington et al. · 2010ReviewUse of ferrous fumarate to fortify foods for infants and young children — [review]View study →}.

For the mineral’s full, form-agnostic evidence base — efficacy across all applications, effect sizes, and the scored evidence table — see the Iron hub. This page does not re-score iron’s applications.

Gap: There is little reason to expect fumarate to differ from other well-absorbed ferrous salts on clinical outcomes once matched for elemental dose; the form-specific literature is mostly bioavailability and tolerability, not distinct efficacy.

Dosage

Iron is dosed as elemental iron, not as the weight of the fumarate salt — this is the single most important labeling point for this form. Because ferrous fumarate is ~33% elemental iron:

• Dietary reference (form-agnostic, from the Iron hub): RDA 8 mg/day (adult men, post-menopausal women), 18 mg/day (menstruating women), 27 mg/day (pregnancy).
• Therapeutic repletion: clinician-directed for a diagnosed deficiency, typically in the range of 40–120 mg elemental iron/day. One 200 mg fumarate tablet (~66 mg elemental) once or twice daily is a common regimen.
• Split and space dosing. Fractional absorption falls as the single dose rises, and a large dose transiently raises hepcidin, which blunts absorption of a second dose given later the same day. Isotope studies show that alternate-day, single morning doses can give higher fractional (and sometimes comparable total) absorption than divided daily dosing, while reducing GI side effects ^{10,11Reference 10Stoffel et al. · 2020RCTIron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient women — [randomized isotope study]View study →Reference 11Moretti et al. · 2015RCTOral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women — [randomized isotope study]View study →}. Lowering the elemental dose or moving to alternate-day dosing is the first lever to pull for tolerability — before switching salts.
• Take with vitamin C, away from inhibitors. Ascorbic acid modestly boosts non-heme iron absorption ^{4Reference 4Mitchikpe et al. · 2010RCTOrange but not apple juice enhances ferrous fumarate absorption in small children — [randomized crossover]View study →}; separate iron from calcium supplements, antacids/PPIs, and tea/coffee.

Doses studied in research, not a personal recommendation. Supplement iron only for a diagnosed need, under clinician guidance. See the Iron hub for full intake references.

Safety

The safety profile is iron’s, not the fumarate ion’s — fumaric acid is a benign dietary acid and normal metabolic intermediate. The form-specific point is that fumarate’s high elemental density means a given tablet count delivers more iron, which matters for both side effects and overdose risk.

• Gastrointestinal. Nausea, epigastric discomfort, constipation and dark stools are the common, dose-related effects of all oral ferrous salts; fumarate is no exception and, in some series, was among the least well tolerated at therapeutic doses ^{5Reference 5Cancelo-Hidalgo et al. · 2013Systematic reviewTolerability of different oral iron supplements: a systematic review — [systematic review, 111 studies]View study →}. Manage by lowering the elemental dose, dosing on alternate days, or taking with food (accepting some loss of absorption).
• Acute overdose — the serious hazard. Iron overdose is dangerous and a leading cause of fatal poisoning in young children; ingestion of iron tablets can cause corrosive GI injury, shock and hepatotoxicity. Because fumarate packs the most elemental iron per tablet of the common salts, accidental pediatric ingestion is correspondingly higher-risk per tablet. Keep away from children.
• Inflammatory bowel disease. In active Crohn disease, a week of oral ferrous fumarate (120 mg) tended to worsen disease-activity scores and depleted plasma antioxidant status (reduced glutathione and cysteine), consistent with oral ferrous iron catalyzing reactive-oxygen production in inflamed gut — IV iron is often preferred in active IBD ^{12Reference 12Hoffmann et al. · 2003Clinical trialFerrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease — [controlled study]View study →}.
• Drug interactions. Iron salts chelate several drugs in the gut. Ferrous fumarate reduced the bioavailability of co-administered ciprofloxacin to ~30% of control ^{13Reference 13Polk et al. · 1990Decreased ciprofloxacin absorption with concomitant administration of ferrous fumarate — [pharmacokinetic study]View study →}; the same applies to other fluoroquinolones, tetracyclines, levothyroxine, and bisphosphonates. Separate iron from these by at least 2–4 hours. Antacids, PPIs and H₂-blockers reduce iron absorption by raising gastric pH.
• Who should be cautious. People with hemochromatosis or iron overload, those receiving repeated transfusions, and anyone without a documented deficiency should not take supplemental iron. Renal and IBD patients should be managed by a clinician.

Pregnancy & lactation

Verdict: appropriate and widely used for diagnosed or at-risk deficiency, under clinician guidance — not a blanket recommendation for all. Oral ferrous fumarate is a standard treatment for iron-deficiency anemia in pregnancy and corrects it effectively, though more slowly than IV iron when deficiency is marked ^{9Reference 9Kriplani et al. · 2017RCTIntravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy: a randomized controlled trial — [RCT]View study →}. At low prophylactic elemental doses it is well tolerated, with GI complaints comparable to bisglycinate and sulfate ^{6Reference 6Milman et al. · 2024RCTLow-dose prophylactic oral iron supplementation (ferrous fumarate, ferrous bisglycinate, and ferrous sulphate) in pregnancy is not associated with clinically significant gastrointestinal complaints: results from two randomized studies — [pooled RCT analysis]View study →}. Iron requirements rise in pregnancy (RDA 27 mg/day), but supplementation should still follow assessment of iron status rather than being assumed universally beneficial.

Scope disclosure (honesty — not a claim):

• Interactions assessed? Yes — fluoroquinolones (ciprofloxacin, documented), and by class: other quinolones, tetracyclines, levothyroxine, bisphosphonates, and acid-suppressing drugs (antacids/PPIs/H₂-blockers) which reduce absorption.
• Pregnancy/lactation assessed? Yes — summarized above; standard for diagnosed/at-risk iron-deficiency anemia under clinician guidance.
• Upper Limit (UL) established? Yes — 45 mg/day elemental iron for adults (from supplements), an iron-wide UL, not fumarate-specific. Therapeutic repletion doses exceed the UL and should be clinician-supervised.

Never imply safety from absence of reports. Where fumarate-specific data are thin (e.g. long-term head-to-head tolerability), that is stated rather than glossed.

Related compounds / cross-links

• Hub: Iron — the full, form-agnostic evidence base, intake references, and safety.
• Sibling forms: Ferrous Sulfate (~20% elemental, cheapest, reference salt, least gentle), Ferrous Gluconate (~12% elemental, gentler, more tablets), Ferrous Bisglycinate (amino-acid chelate, gentlest, premium).
• Enhancer: Vitamin C / Ascorbic acid — modestly increases non-heme iron absorption.

References